Gilead Sciences, Inc. NMS · GILD
Price alert —
Sign in to get a one-time email the moment GILD crosses your price. Free accounts included.
Sign in / create a free accountGilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD last traded at $134.28, down 1.5% on the day; that's in the middle part of its 52-week range ($121.39–$157.29). Right now it's trading close to its recent average, with no strong stretch in either direction.
The next scheduled earnings report (2026-08-06) is the biggest known catalyst on the calendar, and day to day, watch whether it holds above or slips below its recent average.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
KC2 upper, +0.87 ATR from EMA21 — no notable pattern
- · Chop regime — mean-reversion favored both ways
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · KC2 upper stretch — standard mean-reversion tier
- · RSI hook from overbought (57)
- · Chop regime — mean-reversion favored both ways
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
On the latest daily bar, momentum sits mid-range (RSI 57), the trend is quiet (ADX 18), and volume is about normal (0.8×). On the business side, revenue is growing 4% year over year and the business keeps about 27 cents of every sales dollar as free cash.
Latest-bar indicator readings behind the grade — display-only, they don't move the letter.
Company fundamentals for context — display-only, they don't move the grade.
Our cash-flow model pegs fair value near $98.35 (fair range $71–$132); today's price sits 37% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.
- ✓ Positive retained earnings
- ✓ Gross margin 79% (pricing power)
- ✓ Net margin 31%
- ⚠ Debt exceeds cash
- ⚠ Receivables growing faster than revenue
Price implies ~9% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
GILD is a $166.7 billion company, priced at 18× last year's earnings, and it moves more calmly than the market (beta 0.3).
Options idea
See more →About
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to tre…